405 reports of this reaction
0.9% of all ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE reports
#20 most reported adverse reaction
TOOTH INJURY is the #20 most commonly reported adverse reaction for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 405 FDA adverse event reports linking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE to TOOTH INJURY. This represents approximately 0.9% of all 43,023 adverse event reports for this drug.
Patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE who experience tooth injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TOOTH INJURY is a less commonly reported adverse event for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, but still significant enough to appear in the safety profile.
In addition to tooth injury, the following adverse reactions have been reported for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE:
The following drugs have also been linked to tooth injury in FDA adverse event reports:
TOOTH INJURY has been reported as an adverse event in 405 FDA reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TOOTH INJURY accounts for approximately 0.9% of all adverse event reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, making it a notable side effect.
If you experience tooth injury while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.